Integra Lifesciences Stock (NASDAQ: IART)

Integra Lifesciences (NASDAQ:IART) Stock

Integra Lifesciences

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

IART

Earnings

Large Cap

News

Guidance

Health Care

Management

Movers

General

Integra LifeSciences&#39; Q3 results show adjusted EPS of $0.41 and revenue at $380.83 million. Codman segment grows 1%, while Tissue Tech sees a 3.6% decline.

Why Is Integra LifeSciences Stock Soaring On Monday?

Apple, Nio, CVS Health, Stellantis, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Intraday Update

Markets

AIXI

ARRY

ATSG

BBWI

CHWY

FRPT

GSAT

IRON

NGNE

PSNY

PTON

YUMC

Integra LifeSciences Posts Upbeat Results, Joins Air Transport Services, Freshpet, Yum China And Other Big Stocks Moving Higher On Monday

Image47

Price Target

Analyst Ratings

Trading Ideas

Integra LifeSciences Analysts Cut Their Forecasts After Q2 Results

Integra LifeSciences Holdings Corporation - Common Stock

Integra Lifesciences Holdings Corp

WIIM

Integra LifeSciences shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results.

Integra LifeSciences  Sees Q1 Revenue Of $375M - $385M Vs. $411.71M Est; Adj EPS Of $0.40 - $0.45 Vs. $0.56 Est.

Integra LifeSciences Sees FY15 Adj EPS Of $2.41 - $2.51 Vs. $2.51 Est.

Integra LifeSciences Sees FY25 Revenue Of $1.650B - $1.715B Vs. $1.71B Est.

Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) reported quarterly earnings of $0.97 per share which beat the analyst consensus estimate of $0.86 by 12.79 percent. This is a 8.99 percent increase over earnings of $0.89 per share from the same period last year. The company reported quarterly sales of $442.64 million which missed the analyst consensus estimate of $445.15 million by 0.56 percent. This is a 11.49 percent increase over sales of $397.04 million the same period last year.

Earnings Beats

Earnings Misses

Integra Lifesciences Q4 Adj $0.97 Beats $0.86 Estimate, Sales $442.64M Miss $445.15M Estimate

AHCO

ALLT

ARQT

AXGN

AXON

BASE

BGFV

BLZE

BTDR

BWIN

CART

CAVA

CBLL

CCCS

CECO

CGBD

CHRD

CIFR

CPNG

CPSS

DAWN

DNUT

DOCN

DRVN

ELAN

EXLS

FIHL

FLYW

FSLR

FULC

GPOR

HRMY

HSIC

HURN

HYLN

ICCC

IGIC

IMOS

INGN

INTU

INVX

IPAR

ITRI

IVAC

JACK

JAZZ

KEYS

KNSA

LCID

LGIH

LIVN

LMND

LXFR

MASI

MATX

MFIC

MIDD

MMSI

MPLN

MRVI

NOVT

NXRT

Earnings Scheduled For February 25, 2025

Integra LifeSciences Holdings Corporation Subsidiary On Dec. 19 Received FDA Warning Letter; Says Submitted Several Responses To 2024 Form 483s Issued To Each Of The Three Manufacturing Facilities And Is In Process Of Preparing A Written Response To Warning Letter

Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Sell and raises the price target from $16 to $22.

Citigroup Maintains Sell on Integra Lifesciences, Raises Price Target to $22

On Monday, Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) reported third-quarter adjusted EPS of $0.41, down from $0.76 a year ago, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $0.39</a>.
The company reported sales of $380.83 million, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41708174/integra-lifesciences-reports-third-quarter-2024-financial-results" rel="noreferrer noopener">consensus of $375.78 million</a>.
Third-quarter revenues of $380.8 million decreased 0.4% on a reported basis and 8.6% on an organic basis compared to the prior year. Revenue decreased by 10.3% on an organic basis, excluding Boston.
Codman Specialty Surgical&nbsp;segment sales increased 1% to $270.8 million, representing an organic decline of 10.7%. Tissue Technologies revenues were $110.1 million, representing a reported decline of 3.6% and an organic decline of 3.7%.
CEO Transition: Integra also announced Mojdeh Poul as Integra&#8217;s next president and chief executive officer.
Ms. Poul succeeds Jan De Witte, who previously announced he will retire as president and chief executive officer. Ms. Poul will join Integra on January 6, 2025.
Guidance: Integra LifeSciences revises its 2024 revenue outlook to $1.609 billion—$1.619 billion, compared to prior guidance of $1.609 billion—$1.629 billion and the consensus of $1.612 billion.
The company expects 2024 adjusted EPS of $2.41-$2.49, compared to prior guidance of $2.41-$2.57 and the consensus of $2.45.
Integra forecasts fourth-quarter 2024 revenue of $441 million—$451 million and adjusted EPS of $0.81-$0.89, versus the consensus of $448.5 million and $0.87, respectively.
Fourth-quarter guidance reflects the integration of Acclarent, stepped-up revenue from progress clearing the third-quarter shipping holds, and improved production for Integra Skin, partially offset by additional quality holds.
Price Action: IART stock is up 24.30% at $23.97 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41719755/stonepeak-lands-atsg-in-3-1-billion-deal-offering-29-premium-details" target="_blank" rel="noreferrer noopener">Stonepeak Lands ATSG In $3.1 Billion Deal, Offering 29% Premium: Details</a></li>
</ul>

U.S. stocks were lower, with the Dow Jones index falling around 300 points on Monday.
Shares of Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) rose sharply during Monday's session after the company reported better-than-expected third-quarter financial results.
Integra Lifesciences reported quarterly earnings of 41 cents per share which beat the analyst consensus estimate of 39 cents per share. The company reported quarterly sales of $380.83 million which beat the analyst consensus estimate of $375.78 million.
Integra LifeSciences shares jumped 24.4% to $23.96 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares jumped 43% to $66.22 after the company entered a securities purchase agreement for a PIPE investment, expected to bring in gross proceeds of $200 million.</li>
<li>Air Transport Services Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATSG#NASDAQ">ATSG</a>) gained 26.4% to $22.01 after the company announced it will be acquired by Stonepeak for approximately $3.1 billion, with shareholders receiving $22.50 per share in cash.</li>
<li>Xiao-I Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) rose 24.2% to $7.14. Xiao-I entered into private placement &amp; securities purchase agreement to issue, sell convertible promissory note for $2.1 million.</li>
<li>Disc Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) gained 22.9% to $57.93 after the company announced the end of its Phase 2 Bitopertin In Erythropoietic Protoporphyria meeting with the FDA. The company is aligned with the FDA across all proposed study parameters and has a clear development path to registration.</li>
<li>Globalstar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NASDAQ">GSAT</a>) gained 21.8% to $1.6800.</li>
<li>Canopy Growth Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) rose 16% to $5.64.</li>
<li>The Chemours Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>) gained 14.6% to $20.42 after the company reported better-than-expected quarterly financial results.</li>
<li>Array Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) rose 13.5% to $7.61.</li>
<li>Evotec SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NYSE">EVO</a>) jumped 13.1% to $4.3850.</li>
<li>LexinFintech Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LX#NYSE">LX</a>) gained 12.8% to $3.6100.</li>
<li>Freshpet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) gained 10.9% to $148.32 after the company reported better-than-expected quarterly financial results and raised its full-year adjusted EBITDA outlook.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) rose 9.4% to $10.88.</li>
<li>Yum China Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) surged 8.1% to $48.73 after the company reported better-than-expected quarterly EPS and revenues.</li>
<li>Nextracker Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) gained 8% to $42.75.</li>
<li>Peloton Interactive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) rose 7.5% to $7.80.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) gained 7.5% to $1.2250.</li>
<li>Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) gained 7.3% to $29.13 after it was announced that the company will join the S&amp;P MidCap 400 prior to the opening of trading on Wednesday, Nov. 6.</li>
<li>Bath &amp; Body Works, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NASDAQ">BBWI</a>) rose 7.2% to $30.99.</li>
<li>Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) gained 5.6% to $ 38.29</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41713625/this-roblox-analyst-turns-bullish-here-are-top-5-upgrades-for-monday">This Roblox Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday</a></li>
</ul>

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares rose 127.9% to $3.1 during Monday's regular session. The company's market cap stands at $5.7 million. </li>
<li>Singular Genomics Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMIC#NASDAQ">OMIC</a>) stock moved upwards by 58.24% to $21.3. The company's market cap stands at $53.1 million. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares increased by 44.04% to $66.36. The market value of their outstanding shares is at $862.2 million. </li>
<li>Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) stock rose 24.27% to $23.96. The company's market cap stands at $1.8 billion. As per the press release, Q3 earnings came out today. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock rose 23.42% to $1.37. The market value of their outstanding shares is at $22.3 million. </li>
<li>Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) shares moved upwards by 22.19% to $57.59. The market value of their outstanding shares is at $1.7 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>XTL Biopharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTLB#NASDAQ">XTLB</a>) shares decreased by 15.8% to $1.98 during Monday's regular session. The company's market cap stands at $10.7 million. </li>
<li>BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) stock declined by 15.6% to $7.12. The company's market cap stands at $1.4 billion. The company's, Q3 earnings came out today. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) shares declined by 15.57% to $12.1. The market value of their outstanding shares is at $497.2 million. </li>
<li>Cadrenal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) shares decreased by 15.52% to $14.87. The market value of their outstanding shares is at $22.2 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock declined by 13.5% to $2.05. The company's market cap stands at $349.8 million. </li>
<li>Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) stock decreased by 13.3% to $5.35. The market value of their outstanding shares is at $110.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCRX

BSGM

CVKD

DERM

NUWE

OMIC

THRD

TVGN

XTLB

12 Health Care Stocks Moving In Monday's Intraday Session

Integra LifeSciences shares are trading higher after the company reported better-than-expected Q3 financial results.

Integra LifeSciences Expects Q4 2024 Revenue of $441M-$451M Compared To Consensus $448.474M

For the fourth quarter 2024, the Company expects reported revenues in the range of $441 million to $451 million, representing reported growth of 11.1% to 13.6% and organic growth of 2.0% to 4.5%. Fourth quarter guidance reflects the integration of Acclarent, stepped up revenue from progress clearing the third-quarter shipping holds, improved production for Integra Skin, partially offset by additional quality holds. The Company expects adjusted EPS in a range of $0.81 to $0.89.

Integra LifeSciences Expects Q4 2024 Adjusted EPS Of $0.81-$0.89 Compared To Consensus Of $0.87

Integra LifeSciences Expects 2024 Adjusted EPS Of $2.41-$2.49 Compared To Prior Guidance Of  $2.41-$2.57 Vs $2.45 Est.

For the full year 2024, the Company is updating its revenue and adjusted EPS ranges of $1.609 billion to $1.619 billion and $2.41 to $2.49, respectively. The revenue range represents reported growth of 4.4% to 5.0% and
For the full year 2024, the Company is updating its revenue and adjusted EPS ranges of $1.609 billion to $1.619 billion and $2.41 to $2.49, respectively. The revenue range represents reported growth of 4.4% to 5.0% and organic growth of -1.7% to -1.0%.

Integra LifeSciences Expects 2024 Revenue of $1.609B-$1.619B Compared To Prior Guidance Of  $1.609B-$1.629B Vs $1.612B Est.

Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.39 by 5.13 percent. This is a 46.05 percent decrease over earnings of $0.76 per share from the same period last year. The company reported quarterly sales of $380.83 million which beat the analyst consensus estimate of $375.78 million by 1.34 percent. This is a 0.41 percent decrease over sales of $382.42 million the same period last year.

Integra Lifesciences Q3 2024 Adj EPS $0.41 Beats $0.39 Estimate, Sales $380.83M Beat $375.78M Estimate

Integra LifeSciences Has Appointed Mojdeh Poul As The New President And Chief Executive Officer, Effective January 6, 2025, Succeeding Jan De Witte, Who Will Remain President And CEO Until January 6, 2025

Truist Securities analyst Richard Newitter maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Hold and lowers the price target from $26 to $21.

Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $21

B of A Securities analyst Craig Bijou maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Underperform and lowers the price target from $26 to $18.

B of A Securities Maintains Underperform on Integra Lifesciences, Lowers Price Target to $18

Press Releases

Integra LifeSciences Launches Integra Institute for Healthcare Professionals (HCPs)

Integra LifeSciences to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on February 25, 2025

Notice To Long-Term Integra Lifesciences Holdings Corporation (NASDAQ: IART) Shareholders: Grabar Law Investigates Claims on Your Behalf

Legal

Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Globe Life Inc. (NYSE: GL); Paragon 28, Inc. (NYSE: FNA); Integra Lifesciences Holdings Corp. (NASDAQ: IART); Telephone and Data Systems, Inc. (NYSE: TDS); and Methode Electronics, Inc. (NYSE: MEI)

Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Paragon 28, Inc. (NYSE: FNA); Integra Lifesciences Holdings Corp. (NASDAQ: IART); Telephone and Data Systems, Inc. (NYSE: TDS); Methode Electronics, Inc. (NYSE: MEI); and Globe Life Inc. (NYSE: GL)

Jan De Witte joins GHO Capital as Operating Partner

SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Integra LifeSciences Holdings Corp. (NASDAQ: IART) and Encourages Long-Term Integra Investors to Contact the Firm

SHAREHOLDER ALERT: Morris Kandinov Investigating VG, ADSK, DKS, and IART; Shareholders are Encouraged to Contact the Firm

Integra LifeSciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides 2025 Financial Guidance

INTEGRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Integra LifeSciences Holdings Corp. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Comments

Integra Lifesciences

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga